Observational study / 2012
Postdiagnosis soy isoflavone intake of ≥10 mg/day was linked to a statistically significant reduced risk of breast cancer recurrence in US and Chinese women.
Researchers analyzed pooled data from 9,514 breast cancer survivors from two US cohorts and one Chinese cohort to assess the association between postdiagnosis soy isoflavone consumption and breast cancer outcomes. After a mean follow-up of 7.4 years, 1,171 total deaths (881 from breast cancer) and 1,348 recurrences were documented. In pooled analysis, consuming ≥10 mg isoflavones/d was associated with a statistically significant reduced risk of recurrence (HR: 0.75; 95% CI: 0.61, 0.92) and nonsignificant reductions in all-cause mortality (HR: 0.87; 95% CI: 0.70, 1.10) and breast cancer-specific mortality (HR: 0.83; 95% CI: 0.64, 1.07). Isoflavone consumption was inversely associated with recurrence in both US and Chinese women without observed heterogeneity.
Shows an association, not proof of cause and effect.
- Study type
- Pooled prospective cohort study
- Who was studied
- 9,514 breast cancer survivors with invasive breast cancer from 2 US cohorts and 1 Chinese cohort
- What was measured
- All-cause mortality, breast cancer-specific mortality, and breast cancer recurrence
THE PAPER
Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women.
Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, Flatt SW, Zheng Y, Zheng W, Pierce JP, Shu XO. Am J Clin Nutr, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.